INFECTIOUS DISEASES SOCIETY OF AMERICA 2022 GUIDANCE ON THE TREATMENT OF EXTENDED-SPECTRUM β-LACTAMASE PRODUCING ENTEROBACTERALES (ESBL-E), CARBAPENEM-RESISTANT ENTEROBACTERALES (CRE), AND PSEUDOMONAS AERUGINOSA WITH DIFFICULT-TO-TREAT RESISTANCE (DTR-P.

Johns Hopkins University School of Medicine, University of Michigan Health, Louis Stokes Cleveland Veterans Affairs Medical Center, University of Virginia, University of North Carolina School of Medicine, University of Pittsburgh

The Infectious Diseases Society of America (IDSA) aims to offer updated recommendations for clinicians managing infections caused by resistant Gram-negative bacteria. This guidance addresses the challenges posed by extended-spectrum β-lactamase producing Enterobacterales, carbapenem-resistant Enterobacterales, and Pseudomonas aeruginosa with difficult-to-treat resistance. It includes insights into treatment options, resistance mechanisms, and clinical considerations based on the latest evidence.